Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 30 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

7%

2 trials in Phase 3/4

Results Transparency

8%

1 of 13 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

25Total
Not Applicable (9)
Early P 1 (3)
P 1 (10)
P 2 (1)
P 3 (2)

Trial Status

Completed13
Recruiting7
Not Yet Recruiting5
Unknown3
Active Not Recruiting1
Enrolling By Invitation1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 13 completed trials

Clinical Trials (30)

Showing 20 of 20 trials
NCT05516914Phase 1CompletedPrimary

A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors

NCT07026370Enrolling By Invitation

Chinese Population Health and Multimorbidity Study

NCT07112222Phase 1RecruitingPrimary

A Study of LM-350 in Subjects With Advanced Solid Tumours

NCT07327515Not ApplicableNot Yet RecruitingPrimary

PET/CT-Guided Biological Target Volume Delineation and Dose Optimization for Radioactive Seed Implantation Therapy in Malignant Tumors

NCT07277777Phase 2Not Yet RecruitingPrimary

125I Seed Brachytherapy Combined With Immunotherapy for Primary, Recurrent, or Metastatic Malignant Tumors

NCT07301801Early Phase 1RecruitingPrimary

Clinical Application of 68Ga-FL-031 PET in the Diagnosis and Staging of Malignant Tumors

NCT07208487CompletedPrimary

Clinical Study of Pretreatment PET/CT Parameters for Predicting the Efficacy of 125I Seed Implantation in the Treatment of Malignant Tumors

NCT07201259Not Yet RecruitingPrimary

Exploring Gut Microbiome Differences in Female Cancer Patients With Varied Ovarian Function and Fertility Outcomes Following Immune Checkpoint Inhibitor Therapy

NCT07132606Not Yet RecruitingPrimary

The Predictive Value of Serum Histone Succinylation in Malignant Solid Tumors

NCT06270394Not ApplicableCompletedPrimary

FAP PET/CT or PET/MR Production in the Diagnosis, Staging, and Efficacy Assessment of Malignant Tumors Application

NCT07004244Phase 1RecruitingPrimary

Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies

NCT05714748Phase 1Active Not RecruitingPrimary

Application of mRNA Immunotherapy Technology in Epstein-Barr Virus-related Refractory Malignant Tumors

NCT06650566Phase 1RecruitingPrimary

Study of LM-299 in Subjects Advanced Malignant Tumors

NCT06944444Phase 1RecruitingPrimary

A Phase I Clinical Study of SSS59 Monotherapy in Patients With Advanced Malignant Tumors

NCT06753513Not Yet RecruitingPrimary

Clinical Application of 99mTc-FDPH46 SPECT/CT Imaging in Malignant Solid Tumor: a Prospective Exploratory Study

NCT05615974Phase 1RecruitingPrimary

A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors

NCT06740175Not ApplicableCompleted

The Feasibility of Multispectral Optoacoustic Tomography in Different Diseases

NCT05987098Not ApplicableRecruitingPrimary

BBPA PET/CT in Patients With Malignant Tumors

NCT03542773Phase 1Completed

Targeted Imaging of Glutamate Carboxypeptidase II With DCFPyL-PET

NCT05293990Not ApplicableCompletedPrimary

Usefulness of Gadovist-enhanced FLAIR Imaging

Scroll to load more

Research Network

Activity Timeline